Renal Function Among Thalassemia Patients Treated by a Oral Chelator Deferasirox

Key facts

Sponsor

HaEmek Medical Center, Israel

Principal Investigator

Ariel Koren, MD

Ha'Emek Medical Center, Afula, Israel

Intervention

Deferasirox(drug)

Enrollment

36 enrolled

Eligibility

1-45 years · All sexes

Timeline

2011 – 2015

Study locations (1)

• Ha'Emek Medical Center, Afula, Israel

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Rare hereditary hemochromatosis

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT05294471
  Fully Automated High-Throughput Quantitative MRI of the Liver
  University of Wisconsin, Madison

See all trials for Rare hereditary hemochromatosis →